ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 410

Prevalence of Malignancy in Myositis Patients with Anti-aminoacyl-tRNA Synthetase Antibodies: A Single Center Retrospective Study and Literature Review

Taiga Kuga1, Yoshiyuki Abe 2, Kurisu Tada 3, Masakazu Matsushita 1, Ken Yamaji 1 and Naoto Tamura 1, 1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Department of Rheumatology, Juntendo University, Tokyo, Japan, Tokyo, Japan, 3Juntendo University School of Medicine, Tokyo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Amyopathic dermatomyositis, Anti-Synthetase Syndrome and malignancy, Cancer, inflammatory myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Session Title: Muscle Biology, Myositis & Myopathies Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose:

Anti-aminoacyl-tRNA synthetase antibodies (anti-ARS antibodies) are related to Idiopathic Inflammatory Myopathy (IIM) and Anti-Synthetase Syndrome (ASS). While anti-TIF1-γ antibody and anti-NXP-2 antibody are highly related to malignancy, anti-Jo-1 antibody is reported as protective factor against complicating malignancy. We recently experienced a case of anti-PL-7 antibody positive clinically amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP-ILD) and colon cancer (stage Ⅲa). Regarding clinically difficult situation of this case with severe ILD activity and massive tumor indication for surgery, we thought it is important to clarify the risk factors and incidence of malignancy in myositis patients with anti-ARS antibodies.

Methods:

Anti-ARS antibodies were detected by EUROLINE Myositis Profile 3. IIM diagnosis was made by the 2017 EULAR/ACR classification criteria and ‘probable’ cases meeting Bohan And Peter classification were included in this study between 2009 and 2018. Clinical features, laboratory and instrumental data were reviewed in this single center retrospective study. Cancer associated myositis(CAM) was defined by incidence of malignancy within 3 years from the diagnosis of IIM.

Results:

We identified 38 patients positive for Anti-ARS antibodies (Anti-Jo-1 13 cases, Anti-PL-7 12 cases, Anti-PL-12 5 cases, Anti-EJ 8 cases, Anti-OJ 0 case). Malignancies were complicated in 6/38 patients (15.8%, Anti-Jo-1 1/13 case, Anti-PL-7 5/12 cases), while patients negative for anti-ARS antibodies showed lower incidence (8/83 patients, 12.0%). All 6 patients with malignancy complicated with ILD and 3/6 patients (50%) developed RP-ILD. Prevalence of malignancy in Anti-PL-7 antibody positive patients was significantly high compared to other myositis associated antibodies. We then analyzed clinical features, laboratory data of Anti-PL-7 antibody positive patients with or without malignancy. No significant differences in clinical characteristics were seen but interestingly all 3 CADM patients complicated with malignancy.
We identified 429 cases of anti-ARS antibody positive IIM and ASS in the literature. Incidence of malignancy in anti-ARS antibody positive patients was reported around 6% up to 16% and controversial. No patients positive for Anti-PL-7 antibody complicated with malignancy. Anti-Jo-1 antibody showed the highest incidence of malignancy contrary to the previous reports.

Conclusion:

We should pay attention to malignancy screening in anti-ARS antibody positive patients same as other IIMs. Since all CADM patients positive for anti-PL-7 antibody complicated with malignancy, we may need to be cautious of malignancy in anti-PL-7 antibody positive CADM patients. Regarding the high frequency and severity of ILD in anti-ARS antibody positive patients even with malignancy, early detection and intervention of malignancy may lead to beneficial prognosis. 


Disclosure: T. Kuga, None; Y. Abe, None; K. Tada, Eli Lilly and Company, 2; M. Matsushita, None; K. Yamaji, ASAHI KASEI PHARMA, 2, Astellas pharma, 2, 8, bristol myers, 8, Chugai Pharma, 2, Janssen Pharma, 8, Mitsubishi-Tanabe Pharma, 2, 8, Sanofi Pharma, 8, Takeda Pharma, 2; N. Tamura, AbbVie GK, 8, AbbVie pharma, 8, ASAHI KASEI MEDICAL, 2, ASAHI KASEI PHARMA, 2, astellas pharma, 2, 8, Astellas Pharma Inc., 2, 8, AYUMI PHARMA, 2, AYUMI Pharmaceutical Corporation, 2, bristol myers, 8, Bristol-Myers Squibb, 8, Chugai Phamaceutical Co. Ltd., 2, Chugai Pharma, 2, Eisai Co., Ltd., 2, Eisai Pharama, 2, Janssen Pharma, 8, Janssen Pharmaceutical K.K., 8, Mitsubishi Tanabe Pharma Corporation, 2, 8, Mitsubishi-Tanabe Pharma, 2, 8, Sanofi K.K., 8, Sanofi Pharma, 8, Takeda Pharma, 2, Takeda Pharmaceutical Company Ltd., 2.

To cite this abstract in AMA style:

Kuga T, Abe Y, Tada K, Matsushita M, Yamaji K, Tamura N. Prevalence of Malignancy in Myositis Patients with Anti-aminoacyl-tRNA Synthetase Antibodies: A Single Center Retrospective Study and Literature Review [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-malignancy-in-myositis-patients-with-anti-aminoacyl-trna-synthetase-antibodies-a-single-center-retrospective-study-and-literature-review/. Accessed February 6, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-malignancy-in-myositis-patients-with-anti-aminoacyl-trna-synthetase-antibodies-a-single-center-retrospective-study-and-literature-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences